HealthCare Capital Advisors (Harry Venezia)
HealthCare Capital Advisors describes a healthcare-focused investment-banking and advisory practice operating since 2000. Its stated services span private capital raises, M&A, PIPE offerings, strategic partnerships, strategic advice, fairness opinions and valuation analysis.
What stands out about HealthCare Capital Advisors (Harry Venezia)
HealthCare Capital Advisors publicly presents a healthcare-sector advisory model focused on capital formation, M&A, recapitalizations, strategic partnerships and related valuation work. The profile does not identify named completed client transactions or quantitative engagement thresholds.[1][2][3][4][6]
What does HealthCare Capital Advisors (Harry Venezia) do?
HealthCare Capital Advisors identifies itself as a boutique investment-banking and advisory firm specializing in healthcare capital markets since 2000. Harry D. Venezia, Jr. is identified as Managing Director and co-founder, and the team page says he manages the firm’s investment-banking services.
The firm’s public description centers on healthcare capital formation, M&A, strategic partnerships, valuation and fairness-opinion work. Its contact page also describes services for owners seeking to sell a non-strategic asset or monetize an investment through an outright sale or recapitalization.[1][2][3][5]
Publicly listed services include private capital raises for venture capital, private equity and strategic investors; mergers and acquisitions; PIPE offerings; strategic partnerships; strategic advising; fairness opinions; and valuation analysis.
The firm states that it helps clients develop business plans, investor presentations and financial forecasts before entering capital markets. It also describes assistance with identifying and negotiating with strategic partners.[3]
Owners comparing advisory firms can also review Auxo’s M&A advisor vs. business broker vs. investment bank comparison, advisor-selection guide, and sell-side advisor evaluation framework.
What should a business owner evaluate before hiring HealthCare Capital Advisors (Harry Venezia)?
Owners evaluating the firm should confirm how the proposed mandate would be structured across M&A, an outright sale, a recapitalization or capital raising. The firm’s public materials describe positioning for strategic or financial buyers and healthcare investor relationships across the United States, Europe and Asia, but do not provide named completed client transactions in the In The News archive.
Before engagement, an owner should request representative healthcare mandates, the proposed buyer or investor-outreach approach, quantitative engagement criteria, fee and exclusivity terms, conflicts disclosures, the contracting legal entity and the broker-dealer responsible for securities-related activity. The differing references to GT Securities, Inc. and Donald Capital, LLC warrant direct clarification.[1][2][3][4][5][6]
Which legal entity will sign the engagement letter and receive fees
Which broker-dealer currently handles securities offerings for HealthCare Capital Advisors clients—GT Securities, Donald Capital or both—and why do the official pages differ
What are the firm's recent named healthcare M&A, sale, recapitalization and capital-raising mandates
What size transactions and clients does HealthCare Capital Advisors (Harry Venezia) focus on?
HealthCare Capital Advisors states that it serves medical technology, specialty pharmaceuticals, biotechnology, medical devices, healthcare services, healthcare IT and molecular diagnostics.[4]
The In The News archive lists dated market-commentary posts but does not identify named completed client transactions, sold listings or portfolio companies. The May 16, 2025 post discusses mandates, offers and indications of interest without naming a client transaction.[6][7]
The firm states that it works across Series A and B venture capital, private equity, PIPE transactions, strategic buyouts and co-development partnerships. Its contact page describes M&A, sales and acquisition services for owners seeking an outright sale or recapitalization, including positioning for strategic or financial buyers.[4][5]
What does HealthCare Capital Advisors (Harry Venezia) publicly disclose about fees, process and engagement terms?
The firm’s services page does not state minimum revenue, EBITDA, enterprise-value, financing-size or transaction-size thresholds for client engagements.
The In The News archive does not identify named completed client transactions, sold listings or portfolio companies. The About page identifies Donald Capital, LLC as the national broker/dealer relationship but does not explain how that relationship relates to the GT Securities, Inc. attribution shown on the firm’s home and contact pages. The team page does not identify the legal entity that employs Harry Venezia or establish the firm-level regulatory status of HealthCare Capital Advisors itself.[2][3][4][6]
The firm’s home and contact pages state that securities are offered through GT Securities, Inc., member FINRA and SIPC. The About page separately states that HealthCare Capital Advisors works together with Donald Capital, LLC as its national broker/dealer.
FINRA BrokerCheck identifies GT Securities, Inc. as CRD 116012 and Donald Capital LLC as CRD 297763. The About page does not explain how the Donald Capital relationship relates to the GT Securities attribution shown on the home and contact pages. The team page also does not identify the legal entity that employs Harry Venezia or establish the firm-level regulatory status of HealthCare Capital Advisors itself.[1][2][4][5][8][9]
The firm states that it helps clients develop business plans, investor presentations and financial forecasts before entering capital markets and assists with identifying and negotiating with strategic partners. Its public service description also covers capital raising, M&A, strategic partnerships, valuation and fairness-opinion assignments.
The public materials describe investor relationships across the United States, Europe and Asia. Harry Venezia’s team biography says he works directly with more than 800 institutional healthcare investment firms in those regions.[1][2][3]
Questions to ask before hiring HealthCare Capital Advisors (Harry Venezia)
Which legal entity will sign the engagement letter and receive fees?
Which broker-dealer currently handles securities offerings for HealthCare Capital Advisors clients—GT Securities, Donald Capital or both—and why do the official pages differ?
What are the firm's recent named healthcare M&A, sale, recapitalization and capital-raising mandates?
What are the minimum size, revenue, EBITDA or financing criteria for an engagement?
What are the success fee, retainer, expense, exclusivity, termination and tail provisions?
Which team members will lead the assignment, and what conflicts or existing buyer relationships should be disclosed?
Sources & research notes
- Official website / firm overview
- Official website / firm overview
- Services / capabilities
- Industry / market focus
- Transaction / portfolio evidence
- Public disclosure information
- Transaction / portfolio evidence
- FINRA regulatory record
- FINRA regulatory record
How this profile was researched
Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.
Independent research profile
This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.
Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.
Broker-dealer and securities disclosure
Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.
Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.
Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.
Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.
